Alectinib Activity in CNS Metastases in Patients With ALK+ NSCLC Alectinib Activity in CNS Metastases in Patients With ALK+ NSCLC

Two studies report impressive activity for the ALK inhibitor, alectinib, in patients with advanced ALK+ NSCLC -- both in treatment-naive patients and those who have progressed on prior therapy.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news